Literature DB >> 21500339

Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.

Christian P Kratz1, Suthee Rapisuwon, Helen Reed, Henrik Hasle, Philip S Rosenberg.   

Abstract

Noonan syndrome (NS), Costello syndrome (CS), cardiofaciocutaneous syndrome (CFCS), and LEOPARD syndrome (now also referred to as Noonan syndrome with multiple lentigines or NSML) are clinically overlapping dominant disorders that are caused by mutations in RAS signaling pathway genes. The spectrum of cancer susceptibility in this group of disorders has not been studied in detail. We identified more than 1900 cases of NS, CS, CFCS, or NSML reported in the literature between 1937 and 2010; 88 cancers were reported. The most common cancers reported in 1051 NS subjects were neuroblastoma (n = 8), acute lymphoblastic leukemia (n = 8), low grade glioma (n = 6), and rhabdomyosarcoma (n = 6). These associations are biologically plausible, given that somatic RAS pathway mutations are known to occur in these specific cancers. In addition, 40 childhood cases of myeloproliferative disease were described in individuals with NS, several of whom experienced a benign course of this hematologic condition. We confirmed the previously described association between CS and cancer in 268 reported individuals: 19 had rhabdomyosarcoma, 4 had bladder cancer, and 5 had neuroblastoma. By age 20, the cumulative incidence of cancer was approximately 4% for NS and 15% for CS; both syndromes had a cancer incidence peak in childhood. The cancers described in CFCS and NSML overlapped with those reported in NS and CS. Future epidemiologic studies will be required to confirm the described cancer spectrum and to estimate precise cancer risks. Published 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21500339      PMCID: PMC3086183          DOI: 10.1002/ajmg.c.30300

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  27 in total

Review 1.  Noonan syndrome: clinical features, diagnosis, and management guidelines.

Authors:  Alicia A Romano; Judith E Allanson; Jovanna Dahlgren; Bruce D Gelb; Bryan Hall; Mary Ella Pierpont; Amy E Roberts; Wanda Robinson; Clifford M Takemoto; Jacqueline A Noonan
Journal:  Pediatrics       Date:  2010-09-27       Impact factor: 7.124

Review 2.  Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

Authors:  Martin Zenker
Journal:  Horm Res       Date:  2009-12-22

3.  Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype.

Authors:  Simone Martinelli; Alessandro De Luca; Emilia Stellacci; Cesare Rossi; Saula Checquolo; Francesca Lepri; Viviana Caputo; Marianna Silvano; Francesco Buscherini; Federica Consoli; Grazia Ferrara; Maria C Digilio; Maria L Cavaliere; Johanna M van Hagen; Giuseppe Zampino; Ineke van der Burgt; Giovanni B Ferrero; Laura Mazzanti; Isabella Screpanti; Helger G Yntema; Willy M Nillesen; Ravi Savarirayan; Martin Zenker; Bruno Dallapiccola; Bruce D Gelb; Marco Tartaglia
Journal:  Am J Hum Genet       Date:  2010-07-08       Impact factor: 11.025

4.  Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol.

Authors:  Karen W Gripp; Charles I Scott; Linda Nicholson; Donna M McDonald-McGinn; J Daniel Ozeran; Marilyn C Jones; Angela E Lin; Elaine H Zackai
Journal:  Am J Med Genet       Date:  2002-02-15

Review 5.  Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Ann N Y Acad Sci       Date:  2010-10-19       Impact factor: 5.691

6.  Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

Authors:  Hideki Makishima; Heather Cazzolli; Hadrian Szpurka; Andrew Dunbar; Ramon Tiu; Jungwon Huh; Hideki Muramatsu; Christine O'Keefe; Eric Hsi; Ronald L Paquette; Seiji Kojima; Alan F List; Mikkael A Sekeres; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

7.  RAS signaling dysregulation in human embryonal Rhabdomyosarcoma.

Authors:  Simone Martinelli; Heather P McDowell; Silvia Delle Vigne; George Kokai; Stefania Uccini; Marco Tartaglia; Carlo Dominici
Journal:  Genes Chromosomes Cancer       Date:  2009-11       Impact factor: 5.006

8.  Cancer incidence in persons with Fanconi anemia.

Authors:  Philip S Rosenberg; Mark H Greene; Blanche P Alter
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

9.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.

Authors:  Marco Tartaglia; Simone Martinelli; Giovanni Cazzaniga; Viviana Cordeddu; Ivano Iavarone; Monica Spinelli; Chiara Palmi; Claudio Carta; Andrea Pession; Maurizio Aricò; Giuseppe Masera; Giuseppe Basso; Mariella Sorcini; Bruce D Gelb; Andrea Biondi
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

10.  Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.

Authors:  Charlotte M Niemeyer; Michelle W Kang; Danielle H Shin; Ingrid Furlan; Miriam Erlacher; Nancy J Bunin; Severa Bunda; Jerry Z Finklestein; Thomas A Gorr; Parinda Mehta; Irene Schmid; Gabriele Kropshofer; Selim Corbacioglu; Peter J Lang; Christoph Klein; Paul-Gerhard Schlegel; Andrea Heinzmann; Michaela Schneider; Jan Starý; Marry M van den Heuvel-Eibrink; Henrik Hasle; Franco Locatelli; Debbie Sakai; Sophie Archambeault; Leslie Chen; Ryan C Russell; Stephanie S Sybingco; Michael Ohh; Benjamin S Braun; Christian Flotho; Mignon L Loh
Journal:  Nat Genet       Date:  2010-08-08       Impact factor: 38.330

View more
  60 in total

Review 1.  Rhabdomyosarcoma: current challenges and their implications for developing therapies.

Authors:  Simone Hettmer; Zhizhong Li; Andrew N Billin; Frederic G Barr; D D W Cornelison; Alan R Ehrlich; Denis C Guttridge; Andrea Hayes-Jordan; Lee J Helman; Peter J Houghton; Javed Khan; David M Langenau; Corinne M Linardic; Ranadip Pal; Terence A Partridge; Grace K Pavlath; Rossella Rota; Beat W Schäfer; Janet Shipley; Bruce Stillman; Leonard H Wexler; Amy J Wagers; Charles Keller
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

3.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

4.  Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.

Authors:  Yoko Aoki; Tetsuya Niihori; Toshihiro Banjo; Nobuhiko Okamoto; Seiji Mizuno; Kenji Kurosawa; Tsutomu Ogata; Fumio Takada; Michihiro Yano; Toru Ando; Tadataka Hoshika; Christopher Barnett; Hirofumi Ohashi; Hiroshi Kawame; Tomonobu Hasegawa; Takahiro Okutani; Tatsuo Nagashima; Satoshi Hasegawa; Ryo Funayama; Takeshi Nagashima; Keiko Nakayama; Shin-Ichi Inoue; Yusuke Watanabe; Toshihiko Ogura; Yoichi Matsubara
Journal:  Am J Hum Genet       Date:  2013-06-20       Impact factor: 11.025

Review 5.  Developmental disease and cancer: biological and clinical overlaps.

Authors:  Alfonso Bellacosa
Journal:  Am J Med Genet A       Date:  2013-10-07       Impact factor: 2.802

Review 6.  Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association.

Authors:  Mary Ella Pierpont; Martina Brueckner; Wendy K Chung; Vidu Garg; Ronald V Lacro; Amy L McGuire; Seema Mital; James R Priest; William T Pu; Amy Roberts; Stephanie M Ware; Bruce D Gelb; Mark W Russell
Journal:  Circulation       Date:  2018-11-20       Impact factor: 29.690

7.  When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience.

Authors:  Marcello Scala; Pietro Fiaschi; Valeria Capra; Maria Luisa Garrè; Domenico Tortora; Marcello Ravegnani; Marco Pavanello
Journal:  Childs Nerv Syst       Date:  2018-05-24       Impact factor: 1.475

8.  A genome-wide analysis of colorectal cancer in a child with Noonan syndrome.

Authors:  Rahul M Prasad; Rajen J Mody; George Myers; Melisa Mullins; Zaher Naji; James D Geiger
Journal:  Pediatr Blood Cancer       Date:  2018-07-24       Impact factor: 3.167

Review 9.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

Review 10.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.